KRAS and non-small cell lung carcinoma: The excessive signal transduction in NSCLC tumors originates from activating mutations in oncogenes, including KRAS (30%), EGFR (19%), BRAF (5%), HER2 (3%), MET (3%), and ALK (3%) (49).